WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November. On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during t ...

Core Insights - Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases [3] Group 1: Upcoming Events - Aclaris will participate in two healthcare conferences in September 2025 [1] - The first event is a fireside chat at the Cantor Global Healthcare Conference on September 3, 2025, at 1:00 PM EDT [4] - The second event is a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 9:00 AM EDT [4] Group 2: Webcast Information - Live and archived webcasts of both events will be accessible on Aclaris' website for at least 30 days [2]

Core Viewpoint - Aclaris Therapeutics, Inc. reported positive clinical results from its Phase 2a trial of the ITK/JAK3 inhibitor ATI-2138, confirming its tolerability and efficacy, while also validating ITK as a therapeutic target. The company has a strong cash runway expected to fund operations into the second half of 2028, allowing for continued development of its innovative therapies for immuno-inflammatory diseases [1][2]. Pipeline Developments - The company advanced the anti-TSLP monoclonal antibody Bosakitug (ATI-045) into a Phase 2 trial for atopic dermatitis (AD), with patient dosing currently underway [5]. - Dosing has been initiated in the Phase 1a/1b clinical program for the bispecific antibody ATI-052, with expectations to complete the Phase 1a portion by the end of 2025 and provide results in early 2026 [5][6]. Financial Performance - For Q2 2025, Aclaris reported a net loss of $15.4 million, compared to a net loss of $11.0 million in Q2 2024. The total revenue for Q2 2025 was $1.8 million, down from $2.8 million in Q2 2024 [8][9]. - Research and development expenses increased to $11.4 million for Q2 2025, up from $8.8 million in the same period last year, driven by costs associated with clinical development [10]. - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $180.9 million, down from $203.9 million at the end of 2024, but still sufficient to fund operations into the second half of 2028 [7][20]. Leadership Update - Aclaris appointed Roland Kolbeck, Ph.D., as the new Chief Scientific Officer, succeeding Joe Monahan, Ph.D., who will transition to a Special Scientific Advisor role [6].

Core Insights - Aclaris Therapeutics, Inc. will present at the H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025, at 11:30 AM EDT [1] - A live and archived webcast of the presentation will be available on the Aclaris website for at least 30 days [2] - Aclaris is focused on developing novel product candidates for immuno-inflammatory diseases, addressing unmet patient needs [3] Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company with a robust R&D engine and a multi-stage portfolio of product candidates [3] - The company aims to provide treatment options for patients with immuno-inflammatory diseases who currently lack satisfactory therapies [3]

Core Insights - Aclaris Therapeutics, Inc. is participating in two healthcare conferences in March 2025, showcasing its focus on immuno-inflammatory diseases [1][5] - The company is a clinical-stage biopharmaceutical firm developing novel product candidates to address unmet needs in immuno-inflammatory diseases [3] Conference Participation - Aclaris' CEO Dr. Neal Walker and senior leadership will engage in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025, at 3:00 PM EDT [5] - Aclaris will also participate in a virtual fireside chat during the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 9:00 AM EDT [5] Company Overview - Aclaris Therapeutics is focused on developing a pipeline of product candidates aimed at patients with immuno-inflammatory diseases who currently lack satisfactory treatment options [3] - The company boasts a multi-stage portfolio supported by a robust research and development engine [3]